CRAC-HCF 2021 | Embracing China's Pharma Market With Regulatory Compliance and Industry Insights

by Grace Wang Nov 17, 2021

China's Drug Regulation and Pharmaceutical Market Conference, a sub-event of CRAC-HCF 2021 (Chemical Regulatory Annual Conference and Asian Helsinki Chemicals Forum), concluded on Nov. 12. 

Five experts from drug regulation authorities, pharmaceutical companies, and consulting firms decoded drug regulations and analyzed industry dynamics for international pharma companies to develop businesses in the Chinese market.

CRAC-HCF 2021 Virtual Session

China's Pharmaceutical Regulation and Market Overview

Watch the Recording

Topic

Speaker

Interpretation of Chinese Pharmacopoeia 2020 Edition

Ms. Qiaofeng Tao, Vice President of Zhejiang Institute for Food and Drug Control

China Market Entry Strategy for Overseas Pharmaceuticals

Mr. Feng Zhou, Haisco Pharmaceutical Group

Decoding China's Good Pharmacovigilance Practices

Mr. Daniel Yu, Deputy PV Director of Zhejiang Taimei Medical Technology Co., Ltd

Interpretation of China's Marketing Authorization Holder (MAH) System

Ms. Manlu Xia, Industry Expert

Focused Areas and Targets of Innovative Drug Research in China

Mr. Liang Hong, General Manager of Ruiou BaiPharm Service Co., Ltd.

Notes: CRAC-HCF registered participants can download the slides here.

CRAC-HCF Insights on Pharmaceuticals

The Chinese Pharmacopoeia (ChP) is at the core of China's national-level drug standards, said Ms. Qiaofeng Tao, vice president of Zhejiang Institute for Food and Drug Control, an affiliate of Zhejiang Medical Products Administration.

She mentioned that drug registration standards should comply with ChP's general technical requirements, as China's National Medical Products Administration stipulates it. So international companies also have to obey ChP to export drugs to China. [Watch Webinar]

*BaiPharm provides ChP consulting and translation services. BaiPharm has also interpreted the ChP 2020 Edition and its impacts on drug marketing authorization applications.

How Can Foreign Medical Products Embrace the Chinese Market was what Mr. Feng Zhou, business development manager of Haisco, discussed at the conference. He first laid out data which showed that China had become the second-largest pharmaceutical market in the world.

After that, he switched to the market trends in Chinese pharmaceutical market, including that more Chinese companies are turning to innovative drugs due to the fierce competition and low profits in generic drugs.

Mr. Zhou also advised international companies them to understand cultural differences better so that the cooperation with Chinese partners could go smoother. For example, summer vacation is a tradition for Europeans but it's not common for most Chinese professionals.

Hence, to keep projects moving forward while they are on vacation, it's necessary for European companies to make arrangements early, such as transferring drug data to Chinese partners in advance. [Watch Webinar]

China's Good Pharmacovigilance Practices (GVP) is another significant topic for international pharma companies. Mr. Daniel Yu, Deputy Pharmacovigilance Director of Zhejiang Taimei Medical Technology, reminded international companies that China's GVP would take effect on Dec. 1, 2021. [Watch Webinar]

Mr. Yu pointed out that, to better practice the compliance of the pharmacovigilance system, international companies could outsource pharmacovigilance activities such as the processing of individual case study reports (ICSR) to local Chinese service providers. Read BaiPharm's analysis of GVP

The Drug Marketing Authorization Holder (MAH) System also matters in China's drug regulatory framework. MAH system has come into implementation under the Drug Administration Law. In Ms. Manlu Xia's presentation, she elaborated on the main features of China's MAH system, what companies could qualify as MAHs, MAH's responsibilities, and the process of MAH change. [Watch Webinar]

Ms. Xia noted that international MAHs outside China should appoint a Chinese legal person as the local agent. The agent shall assume the same responsibilities and duties as the MAHs.

Besides regulatory affairs, it would be better for an international company to know the moves of competitors. That's what the topic of Popular Fields and Targets of Innovative Drug Researches in China about. [Watch Webinar]

According to Mr. Liang Hong, general manager of Ruiou BaiPharm, antineoplastic drugs are a hot field due to the market opportunities behind the rising number of new cancer cases.

Mr. Hong also analyzed specific antineoplastic drugs that Chinese drug makers were riveted on, e.g., EGFR-TKIs and ALK small-molecule targeted drugs. In terms of the anticancer drugs, some Chinese drug makers have already obtained marketing approval, while some are eyeing the pending approval. Therefore, international companies need to consider carefully before joining the keen competition.

Contact BaiPharm

For every international pharma company intending to start or expand businesses in China, it's essential to ensure regulatory compliance and keep abreast of industry trends.

BaiPharm, a pharmaceutical regulatory consulting service provider based in China, is experienced in market entry projects of finished drugs, APIs, excipients, and packaging materials. BaiPharm also has a global network of offices, business representatives and experts across China, Japan, South Korea, the United States, and Europe to offer 24-hour services to clients.

For China DMF filing/drug registration/GMP/local agent/medical translation services, contact BaiPharm via info@baipharm.com.

Grace Wang
ChemLinked Regulatory Analyst
+ FOLLOW
Copyright: unless otherwise stated all contents of this website are ©2022 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact cleditor@chemlinked.com